Product Description
Mechanisms of Action: Cell Wall Synthesis Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral,Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Argentina | Australia | Austria | Bangladesh | Belgium | Brazil | Canada | Chile | China | Colombia | Croatia | Czech | Denmark | Dominican Republic | Egypt | Finland | France | Germany | Greece | Hong Kong | Iceland | India | Ireland | Italy | Jordan | Luxembourg | Malta | Mexico | Morocco | Netherlands | New Zealand | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Saudi Arabia | Slovakia | Slovenia | South Africa | Sri Lanka | Sweden | Switzerland | Taiwan | Turkey | Ukraine | United Kingdom | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|